Results 121 to 130 of about 105,476 (242)

Post-COVID-19 era heart failure diagnosis and outcomes: adherence to National Institute for Health and Care Excellence Guidelines. [PDF]

Open Heart
Razzaq UB, Docherty KF, Al Ajmi A, Alebraheem A, Burns R, Davie AP, Gan J, Hogg KJ, Jackson CE, Mathioudaki E, Pasupulate R, Piya S, Ritchie L, Simpson J, Steel LC, Wei HN, McMurray JJ, Petrie MC, Campbell RT.   +18 more
europepmc   +1 more source

New biosensors and transgenic mice for multiplex cGMP imaging

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a versatile second messenger that is important for human (patho‐)physiology and pharmacotherapy. Live‐cell imaging of cGMP with biosensors allows to elucidate its spatiotemporal dynamics in real time under close‐to‐native conditions. However, to monitor two separate cGMP pools or cGMP/cAMP
Markus Wolters, Martin Thunemann, Barbara Birk, Susanne Feil, Viacheslav O. Nikolaev, Moritz Lehners, Robert Feil   +6 more
wiley   +1 more source

Can't Patch Everything: Personalized Medicine for Cell Therapy in Dilated Cardiomyopathy

, 2021
Journal of the American Heart Association, EarlyView.
Andrew Sundin, Wayne Balkan, Joshua M. Hare   +2 more
wiley   +1 more source

Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. [PDF]

World J Exp Med
Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N.   +6 more
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Prognostic value of N-terminal pro-B-type natriuretic peptide and C reactive protein testing in patients with acute ST-segment elevation myocardial infarction. [PDF]

Open Heart
Dregoesc IM, Cramariuc D, Wilsgaard T, Istrate M, Buiga VS, Ichim S, Ober C, Manole S, Sharashova E, Stylidis M, Hung J, Iancu AC, Bleie Ø, Steigen T.   +13 more
europepmc   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: A Comparative Study of Biomarkers and Clinical Indicators. [PDF]

Pulm Circ
Huang Y, Qin B, Shen B, Zhu J, Zheng Q, Zheng X, Hu J, Song Y.   +7 more
europepmc   +1 more source

Songorine inhibits mitophagy in chronic heart failure via the TBC1D15/Fis1/Rab7A pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and purpose Songorine (SGR) is an alkaloid extracted from Aconitum carichaelii Debx. and has a demonstrated role in cardiac dysfunction. Chronic heart failure (CHF) is a severe clinical syndrome leading to functional impairment and death, primarily due to the deterioration of energy metabolism in cardiomyocytes. However, the precise
Wenxiu Liu, Xingju Zou, Yang Zheng, Chen Sun, Cheng Peng   +4 more
wiley   +1 more source